Have you treated your patients for any of the following symptoms? Could they be suffering from the effects of a mold related illness?
WE CAN HELP
According to the JAMA, CDC, & EPA
Symptoms of Mold Allergies Include : Sneezing, Chronic cough, Runny nose, Nasal congestion, Itchy, Watery and Red eyes, Skin rashes and hives, Sinus headaches, Reduced lung capacity and difficult breathing.
Toxic Mold Symptoms: Coughing up blood, Nose bleeds, Dizziness, Nausea, Vomiting and Diarrhea. Chest congestion, difficult breathing, Anemia, Skin rashes, Forgetfulness and Memory loss, pulmonary hemorrhage
Toxic mold (Stachybotrys) Black mold or toxic mold contamination has been in the news for several years. Black mold is extremely toxic and can be deadly, especially to children with allergies, and the elderly. Toxic mold has become almost epidemic in U.S. homes. Wallboard, sheetrock or cellulose insulation can act as wicks for any floodwater or unrepaired water leaks. After black mold begins to grow in homes, mold spores are continuously released by the mold clusters. Microscopic mold spores quickly become airborne and travel throughout the air and conditioning and heating systems. A mold infested home creates a lethal environment for anyone predisposed to allergies.
It could be possible that your patient is living in a home that has a severe mold infestation, yet is not aware of it. Dr. Mold Certified Mold Inspection Company can inspect their home, find any visible mold, take air samplings, swab or tape tests, and give a complete and concise report, along with lab results, and then recommend remediation procedures to cleanse the home of all mold spores.
Call Dr. Mold for a Certified Inspection.
Physicians who suspect patient symptoms to be a result of mold exposure may wish to recommend contact Dr. Mold certified Mold Inspection Company 503.706.7070. We conduct mold inspections and testing for Aspergillus and other molds believed to cause invasive fungal infections or allergenic symptoms.
FDA Clears Rapid Test for Aspergillus Infection
The Food and Drug Administration (FDA) today (May 16, 2003) cleared for marketing the first rapid laboratory test for a life-threatening invasive fungal infection that occurs in leukemia patients, organ and bone marrow transplant patients, and patients whose immune systems are compromised by illness or chemotherapy. The test will allow doctors to diagnose invasive aspergillus infection quicker and begin treatment with anti-fungal drugs sooner.
The new test, the Platelia Aspergillus EIA, manufactured by Bio-Rad Laboratories, of Redmond, Wash., detects Aspergillus galactomannan antigen in blood, and is a good indicator of invasive infection. Results are available in about three hours. By comparison, the standard culture method of testing for aspergillus takes a minimum of four weeks before results are available.
‘Earlier detection means earlier and more accurate intervention with life-saving treatment for these critically ill patients, said FDA Commissioner Mark B. McClellan, M.D., Ph.D. One of FDA’s goals is to help make new products that improve medical care available to the public as quickly as possible. FDA cleared the product based on clinical studies of the test’s performance at three cancer centers that showed the test could accurately identify the presence or absence of the aspergillus antigen.
The centers tested 1,890 blood samples collected from 170 patients. Thirty one patients had proven or probable invasive aspergillosis. The new test correctly identified 25 of the 31 people who had aspergillus antigen (80.7% sensitivity). When 148 patients without signs or symptoms of invasive aspergillosis were tested, the test correctly identified 132 of the 148 (89.2% specificity) as not having the antigen.
Although the number of invasive aspergillus cases in the United States is estimated to be only a few thousand per year, the disease is very serious and has a mortality rate of 50%-100%